Katrine L. Henriksen

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Birgitte Rasmussen, Meredith M. Regan, Anne E. Lykkesfeldt et al. · The Lancet Oncology · 2007 · 151 citations

Medicine, Gynecology, Oncology +17

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

Katrine L. Henriksen, Birgitte Rasmussen, Anne E. Lykkesfeldt et al. · Journal of Clinical Pathology · 2006 · 100 citations · Full text

Medicine, Endocrinology, Oncology +17

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

Thomas Frogne, Anne‐Vibeke Lænkholm, Maria Lyng et al. · Breast Cancer Research · 2009 · 72 citations · Full text

Medicine, Molecular Biology, Oncology +16

Pancreatic Bicarbonate Secretion Involves Two Proton Pumps

Ivana Novak, Jing Wang, Katrine L. Henriksen et al. · Journal of Biological Chemistry · 2010 · 60 citations · Full text

Life Sciences, Cell Biology, Physiology +17

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

Katrine L. Henriksen, Birgitte Rasmussen, Anne E. Lykkesfeldt et al. · Acta Oncologica · 2009 · 27 citations · Full text

Medicine, Cancer Biology, Oncology +16